Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 9128 results

  1. Eneboparatide for treating chronic hypoparathyroidism [TSID12145]

    Awaiting development Reference number: GID-TA11713 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. DB-OTO for Hearing loss [ID6728]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Managing common infections - antimicrobial prescribing guidelines

    In development Reference number: GID-NG10050 Expected publication date: TBC

    NICE guideline
    In development

  5. Pelvic floor dysfunction

    Awaiting development Reference number: GID-QS10129 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Setrusumab for treating osteogenesis imperfecta [ID6730]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]

    Awaiting development Reference number: GID-TA11982 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development Reference number: GID-TA10604 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Remdesivir for treating COVID-19 [ID3808]

    Awaiting development Reference number: GID-TA10721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development